Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.66 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Nitrosoglutathione SCHEMBL28090640 | 0.96 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL154574 | 0.96 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL1147641 | 0.96 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL17619393 | 0.96 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL154575 | 0.96 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL30637209 | 0.96 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL28191352 | 0.95 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL29261007 | 0.95 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL28191391 | 0.95 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL6802668 | 0.94 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135396-A1 | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2013006658-A1 | TREATMENT OF ACETAMINOPHEN-INDUCED LIVER DAMAGE BY THE ADMINISTRATION OF MODULATORS OF NITRIC OXIDE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20090253615-A1 | No-modified hemoglobins and uses therefor | DUKE UNIVERSITY (US) | 2009-10-08 | — | — | US | disclosed |
| US-7538193-B2 | NO-modified hemoglobins and uses therefor | DUKE UNIVERSITY (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070275878-A1 | No-modified hemoglobins and uses therefor | DUKE UNIVERSITY | 2007-11-29 | — | — | US | disclosed |
| US-7202340-B2 | No-modified hemoglobins and uses therefor | DUKE UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040132638-A1 | No-modified hemoglobins and uses therefor | DUKE UNIVERSITY | 2004-07-08 | — | — | US | disclosed |
| EP-1015490-B1 | NO-MODIFIED HEMOGLOBINS AND USES THEREFOR | UNIV DUKE (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6627738-B2 | Antiischemic agents; hypotensive agents; antiiflammatory agents | DUKE UNIVERSITY | 2003-09-30 | — | — | US | disclosed |
| US-20020037839-A1 | NO-MODIFIED HEMOGLOBINS AND USES THEREFOR | CONEXANT SYSTEMS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1015490-A1 | NO-MODIFIED HEMOGLOBINS AND USES THEREFOR | DUKE UNIVERSITY MEDICAL CENTER (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998034955-A9 | NO-MODIFIED HEMOGLOBINS AND USES THEREFOR | — | 1999-01-07 | — | — | WO | disclosed |
| WO-1998034955-A1 | NO-MODIFIED HEMOGLOBINS AND USES THEREFOR | DUKE UNIVERSITY MEDICAL CENTER (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253615-A1 | No-modified hemoglobins and uses therefor | HBB, HBG1, HBG2 | PTGS1 48/4885GSTK1 2380/4885GLO1 116/4885 |
| US-20140135396-A1 | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide | OAT, NOS2, NOS3 | PTGS1 6/4885GSTK1 16/4885GLO1 289/4885 |
| US-20040132638-A1 | No-modified hemoglobins and uses therefor | HBB, HBG1, HBG2 | PTGS1 48/4885GSTK1 2380/4885GLO1 116/4885 |
| US-20020037839-A1 | NO-MODIFIED HEMOGLOBINS AND USES THEREFOR | HBB, MB, HMBS | PTGS1 60/4885GSTK1 1429/4885GLO1 373/4885 |
| US-20070275878-A1 | No-modified hemoglobins and uses therefor | HBB, HBG1, HBG2 | PTGS1 48/4885GSTK1 2380/4885GLO1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.